NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR)

R. Boyle; R. Kim; A. Maher; P. Stalley; V. Bhadri

doi:10.1302/1358-992X.2023.3.055

Current issue

General Orthopaedics

NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR)

The New Zealand Orthopaedic Association and the Australian Orthopaedic Association (NZOA AOA) Combined Annual Scientific Meeting, Christchurch, New Zealand, 31 October – 3 November 2022. Part 2 of 2.

R. Boyle
R. Kim
A. Maher
P. Stalley
V. Bhadri

NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR)

Boyle R, Kim R, Maher A, Stalley P, Bhadri V. NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR). Orthop Procs. 2023;105-B(SUPP_3):55-55. doi:10.1302/1358-992X.2023.3.055

Boyle, R., et al. “NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR).” Orthopaedic Proceedings, vol. 105-B, no. SUPP_3, 2023, pp. 55-55., https://doi.org/10.1302/1358-992X.2023.3.055

Boyle, R., Kim, R., Maher, A., Stalley, P., & Bhadri, V. (2023). NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR). Orthopaedic Proceedings, 105-B(SUPP_3), 55-55. https://doi.org/10.1302/1358-992X.2023.3.055

Boyle, R., Kim, R., Maher, A., Stalley, P. and Bhadri, V. (2023) “NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR).” Orthopaedic Proceedings, 105-B(SUPP_3), pp. 55-55. Available at: https://doi.org/10.1302/1358-992X.2023.3.055

Boyle, R., R. Kim, A. Maher, P. Stalley, and V. Bhadri. “NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR).” Orthopaedic Proceedings 105-B, no. SUPP_3 (2023): 55-55. https://doi.org/10.1302/1358-992X.2023.3.055

Boyle R, Kim R, Maher A, Stalley P, Bhadri V. NO MORE SURGERY FOR PVNS? (TENOSYNOVIAL GIANT CELL TUMOUR). Orthop Procs. 2023 Feb 23;105-B(SUPP_3):55-55. https://doi.org/10.1302/1358-992X.2023.3.055

Copy to clipboard

BibTeX

EndNote

RIS

Abstract

PVNS or TGCT (Pigmented Villonodular Synovitis, or Tenosynovial Giant Cell tumour) is a benign tumour affecting the synovial lining of joints and tendon sheaths, historically treated with surgical excision or debridement. We have shown previously this management is fraught with high recurrence rates, especially in its diffuse form. We present the encouraging early results of medical management for this condition with use of a CSF1 inhibitor, in comparison to a cohort of 137 cases previously treated at our institution.

Email: rich_boyle@hotmail.com